Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000740:Anemia / Q000150:complications; D001806:Blood Urea Nitrogen; D002118:Calcium / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009194:Myeloma Proteins / Q000032:analysis; D011379:Prognosis; D012075:Remission, Spontaneous; D012709:Serum Albumin / Q000032:analysis; D012712:Serum Globulins / Q000032:analysis; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D009194:Myeloma Proteins; D012709:Serum Albumin; D012712:Serum Globulins; D014527:Uric Acid; D003520:Cyclophosphamide; D008558:Melphalan; D002118:Calcium